Senti Biosciences Past Earnings Performance
Past criteria checks 0/6
Senti Biosciences's earnings have been declining at an average annual rate of -28.6%, while the Biotechs industry saw earnings growing at 15.9% annually. Revenues have been declining at an average rate of 71.5% per year.
Key information
-28.6%
Earnings growth rate
26.3%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | -71.5% |
Return on equity | -145.6% |
Net Margin | -6,405.1% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Is Senti Biosciences (NASDAQ:SNTI) In A Good Position To Invest In Growth?
Dec 28Will Senti Biosciences (NASDAQ:SNTI) Spend Its Cash Wisely?
Sep 27Senti Biosciences initiated at buy at Chardan on gene circuit synthetic biology platform
Sep 22Senti Biosciences GAAP EPS of -$0.86, revenue of $1.36M
Aug 16Is Senti Biosciences (NASDAQ:SNTI) In A Good Position To Invest In Growth?
Jun 13Revenue & Expenses Breakdown
How Senti Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 1 | -82 | 32 | 0 |
31 Dec 23 | 3 | -83 | 35 | 0 |
30 Sep 23 | 3 | -84 | 37 | 0 |
30 Jun 23 | 4 | -59 | 38 | 0 |
31 Mar 23 | 4 | -52 | 42 | 0 |
31 Dec 22 | 4 | -50 | 38 | 0 |
30 Sep 22 | 5 | -46 | 34 | 0 |
30 Jun 22 | 4 | -46 | 32 | 0 |
31 Mar 22 | 4 | -46 | 22 | 0 |
31 Dec 21 | 3 | -55 | 21 | 0 |
30 Sep 21 | 2 | -45 | 19 | 0 |
31 Dec 20 | 1 | -20 | 9 | 0 |
31 Dec 19 | 0 | -21 | 7 | 0 |
Quality Earnings: SNTI is currently unprofitable.
Growing Profit Margin: SNTI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SNTI is unprofitable, and losses have increased over the past 5 years at a rate of 28.6% per year.
Accelerating Growth: Unable to compare SNTI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SNTI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: SNTI has a negative Return on Equity (-145.59%), as it is currently unprofitable.